PMID- 36516200
OWN - NLM
STAT- MEDLINE
DCOM- 20230417
LR  - 20230507
IS  - 1557-3265 (Electronic)
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 29
IP  - 8
DP  - 2023 Apr 14
TI  - Blood-Based Diagnosis and Risk Stratification of Patients with Pancreatic 
      Intraductal Papillary Mucinous Neoplasm (IPMN).
PG  - 1535-1545
LID - 10.1158/1078-0432.CCR-22-2531 [doi]
AB  - PURPOSE: Intraductal papillary mucinous neoplasm (IPMN) is a precursor of 
      pancreatic ductal adenocarcinoma. Low-grade dysplasia has a relatively good 
      prognosis, whereas high-grade dysplasia and IPMN invasive carcinoma require 
      surgical intervention. However, diagnostic distinction is difficult. We aimed to 
      identify biomarkers in peripheral blood for accurate discrimination. EXPERIMENTAL 
      DESIGN: Sera were obtained from 302 patients with IPMNs and 88 healthy donors. 
      For protein biomarkers, serum samples were analyzed on microarrays made of 2,977 
      antibodies. A support vector machine (SVM) algorithm was applied to define 
      classifiers, which were validated on a separate sample set. For microRNA 
      biomarkers, a PCR-based screen was performed for discovery. Biomarker candidates 
      confirmed by quantitative PCR were used to train SVM classifiers, followed by 
      validation in a different sample set. Finally, a combined SVM classifier was 
      established entirely independent of the earlier analyses, again using different 
      samples for training and validation. RESULTS: Panels of 26 proteins or seven 
      microRNAs could distinguish high- and low-risk IPMN with an AUC value of 95% and 
      94%, respectively. Upon combination, a panel of five proteins and three miRNAs 
      yielded an AUC of 97%. These values were much better than those obtained in the 
      same patient cohort by using the guideline criteria for discrimination. In 
      addition, accurate discrimination was achieved between other patient subgroups. 
      CONCLUSIONS: Protein and microRNA biomarkers in blood allow precise diagnosis and 
      risk stratification of IPMN cases, which should improve patient management and 
      thus the prognosis of IPMN patients. See related commentary by Lohr and Pantel, 
      p. 1387.
CI  - (c)2022 The Authors; Published by the American Association for Cancer Research.
FAU - Zhang, Chaoyang
AU  - Zhang C
AUID- ORCID: 0000-0001-6816-3840
AD  - Division of Functional Genome Analysis, German Cancer Research Center (DKFZ), 
      Heidelberg, Germany.
AD  - Medical Faculty, Heidelberg University, Heidelberg, Germany.
FAU - Al-Shaheri, Fawaz N
AU  - Al-Shaheri FN
AUID- ORCID: 0000-0002-6857-2596
AD  - Division of Functional Genome Analysis, German Cancer Research Center (DKFZ), 
      Heidelberg, Germany.
AD  - Medical Faculty, Heidelberg University, Heidelberg, Germany.
FAU - Alhamdani, Mohamed Saiel Saeed
AU  - Alhamdani MSS
AUID- ORCID: 0000-0001-9168-3895
AD  - Division of Functional Genome Analysis, German Cancer Research Center (DKFZ), 
      Heidelberg, Germany.
FAU - Bauer, Andrea S
AU  - Bauer AS
AUID- ORCID: 0000-0002-7919-0497
AD  - Division of Functional Genome Analysis, German Cancer Research Center (DKFZ), 
      Heidelberg, Germany.
FAU - Hoheisel, Jorg D
AU  - Hoheisel JD
AUID- ORCID: 0000-0002-1583-5049
AD  - Division of Functional Genome Analysis, German Cancer Research Center (DKFZ), 
      Heidelberg, Germany.
FAU - Schenk, Miriam
AU  - Schenk M
AUID- ORCID: 0000-0003-0208-7958
AD  - Department of General Surgery, University Hospital Heidelberg, Heidelberg, 
      Germany.
FAU - Hinz, Ulf
AU  - Hinz U
AUID- ORCID: 0000-0001-8227-968X
AD  - Department of General Surgery, University Hospital Heidelberg, Heidelberg, 
      Germany.
FAU - Goedecke, Philipp
AU  - Goedecke P
AUID- ORCID: 0000-0002-8753-6224
AD  - Department of General Surgery, University Hospital Heidelberg, Heidelberg, 
      Germany.
FAU - Al-Halabi, Karam
AU  - Al-Halabi K
AUID- ORCID: 0000-0001-5269-783X
AD  - Department of General Surgery, University Hospital Heidelberg, Heidelberg, 
      Germany.
FAU - Buchler, Markus W
AU  - Buchler MW
AUID- ORCID: 0000-0002-3666-5675
AD  - Department of General Surgery, University Hospital Heidelberg, Heidelberg, 
      Germany.
FAU - Giese, Nathalia A
AU  - Giese NA
AUID- ORCID: 0000-0001-5920-3142
AD  - Department of General Surgery, University Hospital Heidelberg, Heidelberg, 
      Germany.
FAU - Hackert, Thilo
AU  - Hackert T
AUID- ORCID: 0000-0002-7012-1196
AD  - Department of General Surgery, University Hospital Heidelberg, Heidelberg, 
      Germany.
FAU - Roth, Susanne
AU  - Roth S
AUID- ORCID: 0000-0002-5136-4686
AD  - Department of General Surgery, University Hospital Heidelberg, Heidelberg, 
      Germany.
LA  - eng
PT  - Comment
PT  - Editorial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (MicroRNAs)
RN  - 0 (Biomarkers)
SB  - IM
CIN - Clin Cancer Res. 2023 Apr 14;29(8):1387-1389. PMID: 36719761
CON - Clin Cancer Res. 2023 Apr 14;29(8):1387-1389. PMID: 36719761
MH  - Humans
MH  - *Pancreatic Intraductal Neoplasms/diagnosis/genetics/pathology
MH  - *Adenocarcinoma, Mucinous/diagnosis/genetics/pathology
MH  - *Pancreatic Neoplasms/diagnosis/genetics/metabolism
MH  - Pancreas/pathology
MH  - *Carcinoma, Pancreatic Ductal/diagnosis/genetics/metabolism
MH  - *MicroRNAs/genetics
MH  - Biomarkers
MH  - Hyperplasia
MH  - Risk Assessment
PMC - PMC10102846
EDAT- 2022/12/15 06:00
MHDA- 2023/04/17 06:41
PMCR- 2023/04/14
CRDT- 2022/12/14 13:44
PHST- 2022/08/15 00:00 [received]
PHST- 2022/10/28 00:00 [revised]
PHST- 2022/12/13 00:00 [accepted]
PHST- 2023/04/17 06:41 [medline]
PHST- 2022/12/15 06:00 [pubmed]
PHST- 2022/12/14 13:44 [entrez]
PHST- 2023/04/14 00:00 [pmc-release]
AID - 711665 [pii]
AID - CCR-22-2531 [pii]
AID - 10.1158/1078-0432.CCR-22-2531 [doi]
PST - ppublish
SO  - Clin Cancer Res. 2023 Apr 14;29(8):1535-1545. doi: 10.1158/1078-0432.CCR-22-2531.